Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,243 | -27,698 | -12,568 | -19,435 | -18,552 |
| Depreciation Amortization | 680 | 678 | 677 | 679 | 680 |
| Accounts payable and accrued liabilities | 92 | 105 | 142 | -317 | 198 |
| Other Working Capital | -577 | 2 | 249 | -1,087 | 523 |
| Other Operating Activity | -3,799 | 17,021 | 241 | 2,960 | 3,420 |
| Operating Cash Flow | $-13,847 | $-9,893 | $-11,259 | $-17,201 | $-13,731 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -71 | -7 | -16 | -6 | N/A |
| Investing Cash Flow | $-71 | $-7 | $-16 | $-6 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 15,613 | 21,853 | 4,791 | 16,383 | 9,672 |
| Dividend Paid | N/A | -29 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 2,550 | 0 | 444 | 8,908 |
| Financing Cash Flow | $15,613 | $24,374 | $4,791 | $16,827 | $18,580 |
| Beginning Cash Position | 15,696 | 1,222 | 7,706 | 8,086 | 3,237 |
| End Cash Position | 17,392 | 15,696 | 1,222 | 7,706 | 8,086 |
| Net Cash Flow | $1,695 | $14,475 | $-6,484 | $-380 | $4,849 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,847 | -9,893 | -11,259 | -17,201 | -13,731 |
| Capital Expenditure | -71 | -7 | -16 | -6 | N/A |
| Free Cash Flow | -13,918 | -9,899 | -11,275 | -17,207 | -13,731 |